Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 2 | BMC Pulmonary Medicine

Fig. 2

From: Development and validation of a Guinea pig model for concurrent allergic rhinitis and asthma using recombinant Der f 2

Fig. 2

Recombinant wt Der f 2 protein evokes cutaneous reactions and shows IgE-binding capacity. (a) Skin prick test (SPT) results: The SPT was performed on the forearm of one human volunteer. Recombinant wild-type (wt) and mutant (mu) Der f 2 were applied at concentrations of 20 ng/mL, 200 ng/mL, and 800 ng/mL, along with histamine (positive control) and normal saline (N.S., negative control). Wheal-and-flare reactions were traced with a ballpoint pen. wt Der f 2 elicited significant cutaneous reactions, whereas mu Der f 2 showed a markedly weaker response in the SPT. (b) IgE binding reactivity: Binding reactivity of purified wt and mu Der f 2 to IgE in sera from patients allergic to Dermatophagoides farinae was assessed. The binding capacity of wt Der f 2 to IgE was significantly higher than that of mu Der f 2 (p < 0.01). The antigen concentration used in the assay was 60 ng/mL.

Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us